Drug prices: updated international comparisons

Keith Alcorn, Keith Alcorn
Published: 07 May 2002

This is an updated version of a survey first published in April 2001, covering offers by pharmaceutical companies and generic manufacturers of discounted prices for antiretroviral drugs.

To print this table, we recommend that you select `Landscape` mode by going to Print in your browser and then select `Preferences` in Internet Explorer or `Properties` in Netscape, and adjust the print mode to `Landscape` in the Orientation section.

style='width:100.0%;margin-left:-5.65pt;border-collapse:collapse;border:none;

mso-border-alt:solid windowtext .75pt;mso-padding-alt:5.25pt 5.25pt 5.25pt 5.25pt'>

Generic name

Brand Name

Initials

Manufacturer

Discount Price (on standard dose unless

stated)

Special provisions

Generic Alternative (Country/manufacturer name)

style='font-family:Verdana'>

Protease inhibitors

Lopinavir

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>/ritonavir

Kaletra

N/a

Abbott

c.$650per year

Further cuts promised

Africa


(available to private sector or company health plans and

NGOs, as well as govts)

None

Ritonavir

Norvir

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

N/a

Abbott

c. $650

Further cuts promised

Africa

 

(available to private sector or company health plans and

NGOs, as well as govts)

India (Hetero - c. $4300 p.a.)

Nelfinavir

Viracept

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

N/a

Roche

$1800 p.a

Sub-Saharan Africa

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

(Hetero - $2248 p.a.)

Saquinavir

Fortovase

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

N/a

Roche

c. $670 for SQV when dosed at 1800mg qd

with ritonavir 100mg

 

c.$800 when dosed at 100mg/100mg twice daily

Sub-Saharan Africa

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

(Hetero - $992 p.a.)

Indinavir

Crixivan

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

N/a

Merck

$600 per year

Africa

Romania

Haiti

Brazil


(Available to NGOs and company health plans, as well as govts)

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>:

CIPLA - $2300 p.a at 800mg tid)

Ranbaxy: Virodin

Hetero – Indivir

($1840 p.a. at 800mg tid)

 

Non-nucleoside reverse transcriptase

inhibitors (NNRTIs)

Nevirapine

Viramune

 

Boehringer Ingelheim

Free as two doses for mother and infant treatment

$1.22 per day for adult dosing ($445 p.a)

Maternal/infant treatment free to all non-EU countries

 

(also excludes

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>USA

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>,

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Canada

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>, NZ,

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Australia

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>,

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Japan

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>,

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Switzerland

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>,

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Norway

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>,

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Iceland

style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>)

Nevirapine has been patented in 25 African countries

 

 

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>:

class=SpellE>Cipla (Nevimune $197

p.a. to non-profits)

Ranbaxy: Nevipan

Hetero: Nevivir

Efavirenz

Stocrin

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

N/a

Merck

$500 per year

Africa Romania

Haiti

Brazil ($846 pa)

 

(Available to NGOs and company health plans, as well as

govts)

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

(Aurobindo $485 p.a)

 

Nucleoside analogues (NRTIs)

Stavudine

Zerit

D4T

Bristol

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> Myers

Squibb

15 cents a day/$54 per year

for dose applicable to adults 60kg and over; lower cost

applies at lower body weight

Not available to private sector/company health plans

Note: Stavudine is not patented in any African country

except South Africa

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

 

 

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>:

class=SpellE>Cipla (Stavir;

$40 p.a to non-profits)

Ranbaxy: Virostav

Hetero/Genix Pharma:

style='mso-bidi-font-style:normal'>Stag

Thailand

Brazil

Didanosine

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

Videx

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

DdI

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

Bristol

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> Myers

Squibb

80 cents per day/ $310 p.a. for dose applicable to

adults 60kg and over; lower cost applies at lower body weight

Not available to private sector/company health plans

Note: Didanosine is not

patented in any African country except

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>South

Africa

 

Thailand: non-buffered version Brazil

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

(CIPLA - $584; Aurobindo $190 p.a)

Zidovudine and lamivudine

Combivir

AZT and 3TC

Glaxo Smith Kline

$2 per day

($730 p.a)

Developing countries - govts, NGOs and workplace

initiatives where suitable medical infrastructure exists, via UNAIDS

Accelerating Access Initiative

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

(CIPLA - Duovir $554 pa to

non-profits

Ranbaxy

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> –

class=SpellE>Virocomb

style='mso-spacerun:yes'>  ($346 pa)

Zidovudine

Retrovir

AZT

Glaxo Smith Kline

95% reduction on "average global price"

As above

India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

(CIPLA: Zidovir $306 p.a

lang=NL style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana;

mso-ansi-language:NL'>

Ranbaxy:

style='mso-bidi-font-style:normal'>Viro-2

Hetero: Zido-H

Abacavir

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

Ziagen

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

N/a

Glaxo Smith Kline

 

As above

 

Lamivudine

Epivir

3TC

Glaxo Smith Kline

58 cents per day

As above

Note: Lamivudine is patented in 33 African countries

 

CIPLA -

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

(Lamivir,

30 cents per day to non-profits)

Hetero/GenixPharma:

style='mso-bidi-font-style:normal'>Heptavir (marketed for hepatitis B treatment)

Ranbaxy: Virolam

Zalcitabine

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

Hivid

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

ddC

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

Roche

Available at cost

 

Brazil

 

Combinations

of generics

Lamivudine, zidovudine and nevirapine

 

AZT, 3TC and nevirapine

CIPLA

$350 p.a

Non-profits

(Govts $600 p.a)

 Note: each component of this combination is

patented in 23 African countries

Aurobindo

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> (

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>India

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>)

$295 p.a

Offered to govt health progs

Lamivudine, stavudine and nevirapine

 

3TC, d4T and nevirapine

Hetero (India)

$350 p.a

 

Offered to govt health progs

Note :

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

stavudine dose within these formulations is 40mg bid – lower doses for lower

body weight have not been announced.

Ranbaxy

lang=FR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana;

mso-ansi-language:FR'> (India) –

style='mso-bidi-font-style:normal'>Virolans 30

style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>

 

$388 (295 p.a to MSF and NGOs)

General Pharmaceutical Organization (Thailand)

lang=FR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana;

mso-ansi-language:FR'>

$324 p.a

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.